Want to see HK:6877 full AI Analyst Report?
CLSA Premium Ltd. (6877) AI Stock Analysis
CLSA Premium Ltd.
(HKEX:6877)
The score is held back primarily by weak cash flow and ongoing losses, plus a bearish price trend with the stock trading below key moving averages. Offsetting these risks, the balance sheet is strong with zero debt, and recent revenue growth and gross margin improvement are encouraging but not yet reflected in sustained profitability.
CLSA Premium Ltd. (6877) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 185.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 207.09K
- Price to Earnings (P/E)
- -51.6
- Beta (1Y)
- 0.12
- Revenue Growth
- 70.05%
- EPS Growth
- -221.43%
- Country
- Hong Kong
- Employees
- 15
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Financial - Capital Markets
CLSA Premium Ltd. Business Overview & Revenue Model
Company Description
Engaged in the distribution of health-related goods and services, Top Eminent Healthcare Group Limited operates as an investment holding company, with its activities spanning Australia, Hong Kong, and New Zealand.
CLSA Premium Ltd. Financial Statement Overview
Summary
Financials are mixed. Revenue rebounded strongly and gross margin improved, and the balance sheet is a major positive with zero debt and stable equity. However, profitability is still negative and cash generation is the key weakness, with meaningfully negative operating cash flow and free cash flow in the TTM period.
Income Statement
44NeutralBalance Sheet
82Very PositiveCash Flow
36Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 172.76M | 109.83M | 86.49M | 191.17M | 39.13M | 5.44M |
| Gross Profit | 123.19M | 40.59M | 28.26M | 34.55M | 4.37M | -13.02M |
| EBITDA | -1.85M | -6.50M | -2.54M | 6.97M | -8.17M | -37.05M |
| Net Income | -5.29M | -7.11M | 11.34M | 9.84M | -31.05M | -56.54M |
Balance Sheet | ||||||
| Total Assets | 275.21M | 246.44M | 279.38M | 251.78M | 284.31M | 330.62M |
| Cash, Cash Equivalents and Short-Term Investments | 212.84M | 207.75M | 205.17M | 222.39M | 211.79M | 234.47M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 9.64M |
| Total Liabilities | 32.41M | 5.76M | 35.08M | 11.91M | 53.51M | 61.86M |
| Stockholders Equity | 242.80M | 240.68M | 244.31M | 239.87M | 230.80M | 268.76M |
Cash Flow | ||||||
| Free Cash Flow | -15.13M | -683.00K | -19.90M | 1.82M | -16.79M | -40.12M |
| Operating Cash Flow | -15.13M | -656.00K | -19.90M | 1.82M | -16.79M | -39.26M |
| Investing Cash Flow | 3.80M | -27.00K | 9.48M | 9.64M | 1.78M | 2.21M |
| Financing Cash Flow | 0 | 0 | 0 | -1,000 | -2.12M | -10.14M |
CLSA Premium Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6877, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 35.92 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6877.
CLSA Premium Ltd. Peers Comparison
Overall Rating
HK:071768Neutral
HK:843967Neutral
HK:835064Neutral
HK:107362Neutral- HK:687747Neutral
HK:051039Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0717 | 68Neutral | HKD 377.49M | 2.90 | 3.57% | ― | -22.54% | 60.00% |
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| HK:8439 | 67Neutral | HKD 178.76M | 55.75 | 5.09% | 8.47% | 5.88% | ― |
| HK:8350 | 64Neutral | HKD 350.78M | 3.95 | 57.05% | ― | 280.60% | 330.73% |
| HK:1073 | 62Neutral | HKD 341.80M | 5.92 | 8.47% | 7.20% | 99.18% | 272.34% |
| HK:6877 | 47Neutral | HKD 185.03M | -51.61 | -2.19% | ― | 70.05% | -221.43% |
| HK:0510 | 39Underperform | HKD 194.03M | -4.65 | -23.72% | ― | 10.05% | -40.15% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6877 | CLSA Premium Ltd. | 0.09 | -0.11 | -54.50% | |
| HK:0510 | CASH Financial Services Group | 0.45 | -0.22 | -32.84% | |
| HK:0717 | Emperor Capital Group Limited | 0.06 | -0.05 | -48.62% | |
| HK:1073 | Da Yu Financial Holdings Limited | 0.10 | -0.02 | -13.79% | |
| HK:8350 | Excalibur Global Financial Holdings Limited | 0.36 | 0.00 | 0.00% | |
| HK:8439 | Somerley Capital Holdings Ltd | 1.18 | 0.88 | 297.31% |
CLSA Premium Ltd. Corporate Events
Top Eminent Healthcare Returns to Profit on Strong Healthcare Product Sales
Top Eminent Healthcare Group Limited reported a 64.9% jump in total income to HK$74.5 million for the six months ended 30 June 2026, driven by a 70.5% surge in revenue from its healthcare products business to HK$70.9 million. The company maintained a...
Top Eminent Healthcare Schedules Board Meeting to Approve Interim Results
Top Eminent Healthcare Group Limited announced that its board will convene a meeting on 17 August 2026 to approve and publish the interim results for the six months ended 30 June 2026. The board will also consider the declaration of an interim divide...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 11, 2026